<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980132</url>
  </required_header>
  <id_info>
    <org_study_id>LIGRADIS</org_study_id>
    <nct_id>NCT03980132</nct_id>
  </id_info>
  <brief_title>Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.</brief_title>
  <acronym>LIGRADIS</acronym>
  <official_title>Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jesús María Villar del Moral</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>José Luis Muñoz de Nova - H. U. La Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guzmán Franch Arcas - C. A. U. Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nuria Muñoz Pérez - H. U. Virgen de las Nieves</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aitor de la Quintana Basarrate - H. U. Cruces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oscar Vidal Pérez - H. Clinic Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>José Manuel Rodríguez González - H. C. U. Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pablo Moreno Llorente - H. U. Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>María Isabel Gutiérrez Giner - H. U. Insular de Gran Canaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francisco Javier Guadarrama González - H. U. 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irene Osorio Silla - H. U. Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enrique Mercader Cidoncha - H. G. U. Gregorio Marañón</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joaquín Gómez Ramírez - H. U. Ramón y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mariano Artés Caselles - H. U. Puerta de Hierro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lander Gallego Otaegui - H. U. Donostia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elena Gamborino Caramés - H. C. U. Santiago de Compostela</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juan Manuel Martos Martínez - H. U. Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joaquín Ortega Serrano - H. C. U. Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Susana Ros López - H. C. U. Lozano Blesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, both the American Thyroid Association and the European Thyroid Association
      recommend the use of Lugol Solution (LS) in the preparation of patients undergoing
      thyroidectomy for Graves' disease (GD), but their recommendations are based on a low level of
      evidence. This means that its use is not generalized among the different endocrine surgery
      units.

      Methods:

      Study population: 270 patients (135 patients in each arms) undergoing total thyroidectomy
      (TT) due to GD in Spanish hospitals, which perform a minimum of 100 thyroidectomies a year,
      at least 10 of them for GD.

      Variables:

      Preoperative variables

        -  Demographic variables: birthdate, gender and ethnicity.

        -  Drugs allergies. Allergy to iodine.

        -  Personal history and usual treatment.

        -  Aspects related to the GD: date of diagnosis, use of AT drugs and/or radioiodine,
           existence of ophthalmopathy, existence of cervical compression symptoms and indication
           of surgery.

        -  Physical exploration: body mass index, pulse at rest and blood pressure and cervical
           palpation.

        -  Laboratory tests: hematocrit, leukocytes, neutrophils, platelets, international
           normalized ratio(INR), creatinine, potassium, total calcium, albumin, total proteins,
           parathormone (PTH), 25-hydroxide-vitamin D, free T4 and / or free T3, TSH, thyroid
           stimulating immunoglobulin (TSI).

        -  Classification of the anesthetic risk of ASA.

        -  Cervical ultrasound: existence of thyroid nodules and volume of the thyroid.

        -  Mobility of the vocal cords evaluated by laryngoscopy.

        -  Compliance with assigned treatment: the patient assigned to the LS arm must have
           consumed at least 80% of the total dose indicated.

      Intraoperative variables

        -  Surgical time.

        -  Antibiotic prophylaxis

        -  Intraoperative hemorrhage.

        -  Thyroidectomy Difficulty Scale.

        -  Loss of electromyographic signal during neural intraoperative monitorization.

        -  Accidental parathyroidectomy.

        -  Section or obvious lesion of the recurrent laryngeal nerve.

        -  Trachea or esophagus perforation.

        -  Weight of the gland.

        -  Electrosurgical hemostasis system used during the intervention.

        -  Maneuvers used to check hemostasis.

        -  Hemostats used during the intervention.

        -  Use of drainage.

        -  Definitive surgical technique: TT, unilateral or bilateral subtotal thyroidectomy or
           hemithyroidectomy.

      Postoperative variables

        -  Early complications: hypoparathyroidism, paralysis of the recurrent laryngeal nerve,
           postoperative hematoma, surgical site infection or death.

        -  Debit for surgical drains.

        -  Postoperative hospital long of stay.

        -  Anatomopathological variables: histological diagnosis compatible with GD and existence
           of parathyroid glands in the surgical specimen.

        -  Long-term complications: hypocalcemia and/or permanent vocal cord paralysis longer than
           6 months
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>To analyze whether, in euthyroid patients undergoing TT due to GD, preoperative non-preparation with LS increases the appearance of postoperative complications compared to the use of LS preparation. The main variable will be the rate of postoperative complication: hypoparathyroidism, recurrent laryngeal nerve injury, hematoma, surgical site infection or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical difficulty</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Score of the difficulty of the surgery by the surgeon through the Thyroidectomy Difficulty Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative hemorrhage</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Amount of blood lost during the thyroidectomy in dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical time.</measure>
    <time_frame>Intraoperatively.</time_frame>
    <description>Time from surgical incision to skin closure in minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative neuromonitoring.</measure>
    <time_frame>Intraoperatively.</time_frame>
    <description>Rate of patients with loss of electromyographic signal during intraoperative neuromonitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Long of Stay</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Days to hospital discharge after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>30 days after surgery.</time_frame>
    <description>Rate of readmissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent complications</measure>
    <time_frame>180 days after surgery</time_frame>
    <description>Rate of patients with permanent complications, including hypoparathyroidism or recurrent laryngeal nerve injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>180 days after surgery</time_frame>
    <description>Number of patients with an adverse event after administration of Lugol solution.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Hyperthyroidism, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Preoperative Lugol Solution preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Lugol Solution preparation for 10 days before thyroidectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No preparation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive preparation before thyroidectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lugols Strong Iodine</intervention_name>
    <description>5 L.I. drops / 8 hours for 10 days before surgery</description>
    <arm_group_label>Preoperative Lugol Solution preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet all of the following criteria will be eligible:

          -  The age of the patient must be over 18 years of age.

          -  The patient or his / her tutor, in cases where this is the case, has the capacity to
             understand the study and agrees to participate in it, by signing the corresponding
             informed consent document.

          -  Patients who have been diagnosed with GD, defined as the existence of hyperthyroidism
             (TSH &lt; lower limit of laboratory normality associated with TSI &gt; upper limit of
             laboratory normality) that present ultrasonographic data (diffuse vascularization
             increase) and / or scintigraphy (diffuse uptake of the radioisotope) compatible with
             GD.

          -  Euthyroid patients (free T4 and / or free T3 within the normal range of the
             laboratory) at the time of randomization, and under treatment with AT drugs
             (propylthiouracil, carbimazole or methimazole).

          -  The patient must be proposed for total thyroidectomy, using a transcervical approach.

        Exclusion Criteria:

        The participant can not participate in the study if he / she presents any of the following
        circumstances:

          -  Prior cervicotomy by surgical intervention on the thyroid or parathyroid gland.

          -  Associated hyperparathyroidism that requires associating a parathyroidectomy in the
             same surgical act.

          -  Associated thyroid cancer that requires adding a lymph node dissection of the central
             or lateral compartment in the same surgical time.

          -  Iodine allergy.

          -  Consumption of lithium or amiodarone between randomization and administration of LS.

          -  Patients with category IV of the anesthetic risk classification of the American
             Society of Anesthesiologists (ASA).

          -  Women who breastfeed during the administration of the LS or in the month after it.

          -  Preoperative palsy of a vocal cord verified by laryngoscopy.

          -  Surgery performed by training specialists, or by staff not specifically dedicated to
             endocrine surgery.

          -  Surgery not performed under general anesthesia.

          -  Endoscopic surgery, video assisted or by remote approach.

          -  Surgery performed in out-patient settings.

          -  Current drug consumption or alcohol abuse that could interfere with meeting the study
             requirements.

          -  Participation in any other trial with medications in the month prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario de La princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Muñoz de Nova, MD</last_name>
      <phone>+34915202447</phone>
      <email>jmunoz@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>José Luis Muñoz de Nova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>February 22, 2020</last_update_submitted>
  <last_update_submitted_qc>February 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Jesús María Villar del Moral</investigator_full_name>
    <investigator_title>Head of General and Digestive Surgery - H. U. Virgen de las Nieves</investigator_title>
  </responsible_party>
  <keyword>Thyroid Surgery</keyword>
  <keyword>Grave' Disease</keyword>
  <keyword>Lugol Solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

